Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 884

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children

Open access
Busse, William W., Morgan, Wayne J., Gergen, Peter J., Mitchell, Herman E., Gern, James E., Liu, Andrew H., Gruchalla, Rebecca S., Kattan, Meyer, Teach, Stephen J., Pongracic, Jacqueline A., Chmiel, James F., Steinbach, Suzanne F., Calatroni, Agustin, Togias, Alkis, Thompson, Katherine M., Szefler, Stanley J., Sorkness, Christine A.·2011·New England Journal of Medicine
DOI 10.1056/nejmoa1009705
Open this paper in CoChat — free account

Abstract

BACKGROUND: Research has underscored the effects of exposure and sensitization to allergens on the severity of asthma in inner-city children. It has also revealed the limitations of environmental remediation and guidelines-based therapy in achieving greater disease control. METHODS: We enrolled inner-city children, adolescents, and young adults with persistent asthma in a randomized, double-blind, placebo-controlled, parallel-group trial at multiple centers to assess the effectiveness of omalizumab, as compared with placebo, when added to guidelines-based therapy. The trial was conducted for 60 weeks, and the primary outcome was symptoms of asthma. RESULTS: Among 419 participants who underwent randomization (at which point 73% had moderate or severe disease), omalizumab as compared with placebo significantly reduced the number of days with asthma symptoms, from 1.96 to 1.48 days per 2-week interval, a 24.5% decrease (P<0.001). Similarly, omalizumab significantly reduced the proportion of participants who had one or more exacerbations from 48.8 to 30.3% (P<0.001). Improvements occurred with omalizumab despite reductions in the use of inhaled glucocorticoids and long-acting beta-agonists. CONCLUSIONS: When added to a regimen of guidelines-based therapy for inner-city children, adolescents, and young adults, omalizumab further improved asthma control, nearly eliminated seasonal peaks in exacerbations, and reduced the need for other medications to control asthma. (Funded by the National Institute of Allergy and Infectious Diseases and Novartis; ClinicalTrials.gov number, NCT00377572.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1009705

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 884

Metadata

Authors
Busse, W. W., Morgan, W. J., Gergen, P. J., Mitchell, H. E., Gern, J. E., Liu, A. H., Gruchalla, R. S., Kattan, M., Teach, S. J., Pongracic, J. A., Chmiel, J. F., Steinbach, S. F., Calatroni, A., Togias, A., Thompson, K. M., Szefler, S. J., & Sorkness, C. A.
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2011-03-17
Volume
364
Issue
11
Pages
1005-1015
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa1009705
OpenAlex
W2146852572
Cited by
884
References
6
FWCI
39.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children. https://app.cochat.ai/papers/10.1056/nejmoa1009705
The paper
Busse, W. W., Morgan, W. J., Gergen, P. J., Mitchell, H. E., Gern, J. E., Liu, A. H., Gruchalla, R. S., Kattan, M., Teach, S. J., Pongracic, J. A., Chmiel, J. F., Steinbach, S. F., Calatroni, A., Togias, A., Thompson, K. M., Szefler, S. J., & Sorkness, C. A. (2011). Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1009705

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.